TJ-M2010-5 (TJ-5), a novel CNS drug candidate with good blood–brain barrier permeability, is a specific inhibitor of MyD88, which also blocks signaling in the TLR4/MyD88/NF-kB pathway, and a study has shown that this targeted inhibitor significantly suppressed the excessive inflammatory response in a rat model of cerebral ischemia–reperfusion injury and reduced the rat cerebral infarction area (Li et al., 2022f). The gene discussed is TLR4; the disease is brain ischemia.